Latham, Goodwin Procter Lead $1.3B Biopharma Merger
Akebia Therapeutics, led by Latham & Watkins LLP, and Keryx Biopharmaceuticals, advised by Goodwin Procter LLP, will merge in an all-stock deal poised to create a $1.3 billion, Massachusetts-based biopharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article